Select to order medicines [Delhi/NCR /Bangalore /Chennai /Bhubaneswar /Mumbai]
There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
Studies in breastfeeding mothers have demonstrated that there is significant and documented risk to the infant based on human experience, or it is a medication that has a high risk of causing significant damage to an infant. The risk of using the drug in breastfeeding women clearly outweighs any possible benefit from breastfeeding. The drug is contraindicated in women who are breastfeeding an infant.
Typical usage: Acute leukemia, beta thalassaemia, chronic myeloid leukaemia, myeloproliferative disorders, sickle cell anaemia, solid tumor.
Side Effects: Fever, hyperuricemia, elevated hepatic enzymes, malaise, dysuria, impaired renal tubular function, increased blood urea nitrogen, increased creatinine, chills, dizziness, drowsiness, alopecia, anorexia, diarrhea, constipation, rashes, erythema, hallucination, stomatitis, disorientation, nausea and vomiting, convulsions.
Drug Interaction: Acute leukemia, beta thalassaemia, chronic myeloid leukaemia, myeloproliferative disorders, sickle cell anaemia, solid tumor.
Mechanism Of Action: Hydroxycarbamide causes inhibition of DNA synthesis during the S-phase of cell division by acting as a ribonucleotide reductase inhibitor resulting to cell death. It is S-phase specific.